ArticleFrontiers in veterinary science2025
Development and evaluation of clove oil nanoemulsion-based topical cream for anti-inflammatory activity in mice.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro Antifungal Activity of Essential Oils and Nanoemulsions ofAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory skin disorders require effective topical therapies with minimal side effects. Clove (Syzygium aromaticum) is recognized for its potent anti-inflammatory, antimicrobial, and antioxidant properties, but it has a limited clinical use due to its highly volatile nature, poor solubility, and potential skin irritation at higher concentrations. This research aimed to develop and optimize clove oil nanoemulsion (CONE)-based topical cream, characterize its physicochemical properties, and evaluate anti-inflammatory efficacy using a mouse model. Methodology & Results: CONE was prepared via ultrasonication and optimized using response surface methodology. The optimized CONE exhibited a mean droplet size of approximately 190 nm and Polydispersity Index of 0.08, with high entrapment efficiency (94.54%). GC-MS analysis confirmed eugenol as the major constituent. The nanoemulsion demonstrated strong antifungal activity. The minimum inhibitory concentration was 120 μl/mL. CONE significantly enhanced antioxidant capacity compared to clove oil. The cream was formulated by incorporating CONE into carboxymethyl cellulose (CMC) matrix and evaluated for stability, pH, morphology, and drug release. The cream maintains stability, favorable organoleptic properties, and sustained drug release, particularly at a 1 mL CONE concentration. Thirty adult male albino mice (30-40g) were used and randomly divided into six groups. Hematological parameters and C-reactive protein level further supported the anti-inflammatory efficacy topical cream, with marked improvements observed in treated groups. Histopathological analysis revealed re-epithelialization and diminished inflammatory infiltration. Conclusion: CONE-based cream offers a promising, safe, and effective topical therapy for inflammatory skin conditions. The nanoemulsion formulation enhances clove oil's bioavailability, stability, and therapeutic potential, supporting further development for clinical and cosmetic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.